Know Cancer

or
forgot password

International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC)


N/A
18 Years
N/A
Open (Enrolling)
Both
Carcinoma, Hepatocellular

Thank you

Trial Information

International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC)


Inclusion Criteria:



- In- and outpatients with diagnosis of hepatocellular carcinoma (HCC) and decision
taken by the investigator to prescribe Nexavar

Exclusion Criteria:

- Exclusion criteria must be read in conjunction with the local product information

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Efficacy: status of tumor, patients performance status

Outcome Time Frame:

At each follow-up visit, every 2-4 months

Safety Issue:

No

Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:

Bayer

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

14690

NCT ID:

NCT00792350

Start Date:

April 2008

Completion Date:

December 2013

Related Keywords:

  • Carcinoma, Hepatocellular
  • Carcinoma, Hepatocellular
  • Sorafenib
  • Carcinoma
  • Carcinoma, Hepatocellular

Name

Location